Abstracts Archive - Page 1868 of 2607 - ACR Meeting Abstracts

Abstract Number: 3216 • 2015 ACR/ARHP Annual Meeting
T Cell Restricted Deletion of Serine/Arginine-Rich Splicing Factor 1 (SRSF1) in Mice Causes Immune Cell Dysfunction and Contributes to Lupus-like Nephritis
Vaishali R. Moulton¹, Michael W. Mosho², Hao Li², Andrew R. Gillooly² and George C. Tsokos³, ¹Medicine/Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Medicine/ Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: T cells from patients with systemic lupus erythematosus (SLE) express reduced amounts of the critical CD3 zeta signaling chain, and are poor producers of…
Abstract Number: 3217 • 2015 ACR/ARHP Annual Meeting
Macrophage Depletion Using a Specific CSF-1R Kinase Inhibitor Ameliorates Kidney and Skin Disease in a Mouse Model of Systemic Lupus Erythematosus
Jessica Doerner¹, Samantha Chalmers² and Chaim Putterman³, ¹Albert Einstein College of Medicine, Bronx, NY, ²Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, NY, ³The Division of Rheumatology, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Kidney and skin involvement are common in systemic lupus erythematosus (SLE). Nephritis is seen in up to 60% of patients, and contributes significantly to…
Abstract Number: 3218 • 2015 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Placebo-Controlled, 52-Week Study of the Efficacy and Safety of Belimumab Administered Subcutaneously Plus Standard Care to Patients with Systemic Lupus Erythematosus (SLE)
William Stohl¹, Andreas Schwarting², Masato Okada³, Morton Scheinberg⁴, Andrea Doria⁵, Anne Hammer⁶, Christi Kleoudis⁷, Damon Bass⁸, James Groark⁹, Norma Lynn Fox¹⁰, David Roth¹¹ and David Gordon¹¹, ¹Division of Rheumatology, University of Southern California Keck School of Medicine, Los Angeles, CA, ²ACURA Kliniken, Bad Kreuznach, Germany, ³Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁴Rheumatology Hospital Abreu Sodre Pesquisa Clínica, São Paulo, Brazil, ⁵Division of Rheumatology, University of Padova, Padova, Italy, ⁶GlaxoSmithKline, Research Triangle Park, NC, ⁷Parexel, Durham, NC, ⁸Immuno-Inflammation, GlaxoSmithKline, King of Prussia, PA, ⁹GlaxoSmithKline, Philadelphia, NC, ¹⁰GlaxoSmithKline, Washington, MD, ¹¹GlaxoSmithKline, Philadelphia, PA
Background/Purpose: To assess the efficacy and safety of belimumab (BEL) administered subcutaneously plus standard SLE care (SoC) in patients with active SLE.Methods: BLISS-SC (BEL112341; NCT01484496)…
Abstract Number: 3219 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of 4 Weeks Administration of Arsenic Trioxide in Moderate Active Systemic Lupus Erythematosus. a Phase I/II Proof-of-Concept Sequential Dose Escalation Multicenter Study
Mohamed Hamidou¹, Benjamin Gaborit², Eric Hachulla³, Zahir Amoura⁴, Mikael Ebbo⁵, Emmanuel Chatelus⁶, Jean Sibilia⁷, Jean-Francois Viallard^8,9, Julie Graveleau¹, Melanie Saint Jean¹⁰, Sandrine Gardes¹¹, Yohann Foucher¹¹, Christelle Volteau¹², Joel Poupon¹³, Antoine Neel¹⁴ and François Rieger¹⁵, ¹Internal Medicine Department, Nantes University Hospital, Nantes, France, ²Internal Medicine, Department of Internal Medicine, Nantes University Hospital, Nantes, France, ³Department of Internal Medicine, University Lille Nord-de-France, Lille, France, ⁴Internal Medecine - Centre de Référence National pour les Lupus et et le Syndrome des Antiphospholipides, Pitié-Salpêtrière hospital, Paris, France, ⁵Internal Medicine, Aix-Marseille Université, AP-HM, Marseille, France, ⁶Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁷Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁸Internal Medecine, Haut Lévèque Hospital, Bordeaux, France, ⁹Hôpital Haut-Lévêque, Bordeaux, CHU Bordeaux, France, ¹⁰Department of Dermatology, Nantes University Hospital, Nantes, France, ¹¹Nantes Universitary Hospital, Nantes, France, ¹²Clinical Research Department, Nantes University Hospital, Nantes, France, ¹³Paris University, Paris, France, ¹⁴Department of Internal Medicine, Nantes University Hospital, Nantes, France, ¹⁵MEDSENIC, Hôpital Cochin, Paris Descartes University, Paris, France
Background/Purpose: Arsenic Trioxide (ATO) is approved for the treatment of acute promyelocytic leukemia, increasing oxidative stress with selective apoptosis of leukemia cells. In MLR/lpr model…
Abstract Number: 3220 • 2015 ACR/ARHP Annual Meeting
Anifrolumab Differentially Suppresses Peripheral Biomarkers of Systemic Lupus Erythematosus Compared with Placebo in a Phase IIb Trial
Xiang Guo¹, L Wang², G Illei³, P Brohawn¹, Brandon Higgs¹ and Wendy White¹, ¹Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ²MedImmune, Gaithersburg, MD, ³Clinical Development, MedImmune, LLC, Gaithersburg, MD
Background/Purpose: Anifrolumab is a fully human IgG1 κ monoclonal antibody directed against subunit 1 of the type I interferon receptor (IFNAR1). A Phase IIb randomized,…
Abstract Number: 3221 • 2015 ACR/ARHP Annual Meeting
Safety and Efficiency of Low-Dose Interleukin-2 Treatment in Systemic Lupus Erythematosus
Jing He¹, Xia Zhang², Yunbo Wei³, Xiaolin Sun⁴, Jianping Guo⁵, Yuebo JIn⁶, Rulin Jia⁶, Lei Zhu⁶, Zhaohua Hou⁷, Yaping Chen⁸, Yuan An⁶, Yuan Jia⁶, Xu Liu⁶, Limin Ren⁶, Ru Li⁶, HUA YE⁹, Shi Chen⁶, Xuewu Zhang¹⁰, Yin Su¹¹, Eric Morand¹², Yu Di¹³ and Zhanguo Li⁶, ¹Peking Univerisity People's Hospital, Beijing, China, ²Department of Rheumatology & immunology, Peking University People's Hospital, Beijing, China, ³Immunology for Environment and Health, Shandong Analysis and Test Center, Shandong Academy of Science, Shandong, China, ⁴People's hospital,Peking University, Beijing, China, ⁵Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ⁶Peking University People's Hospital, Beijing, China, ⁷Shandong Analysis and Test Center, Beijing, China, ⁸Monash University, Clayton, Austria, ⁹No.11 XIZHIMENG SOUTH STREET,, Peking University People's Hospital, Beijing, China, ¹⁰Rheumatology, Peking University People's Hospital, Beijing, China, ¹¹Department of Rheumatology and Immunology,Clinical Immunology Center, Peking University People's Hospital, Beijing, China, ¹²Medicine, Monash University, Clayton, Australia, ¹³Molecular Immunomodulation Laboratory, Monash University, Clayton, Austria
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with multi-system involvement, associated with an imbalance between effector and regulatory CD4+ T cells. The…
Abstract Number: 3222 • 2015 ACR/ARHP Annual Meeting
Repeated Administration of Dapirolizumab Pegol (DZP) Appears Safe and Well Tolerated in Patients with Systemic Lupus Erythematosus (SLE) and Is Accompanied By an Improvement in Disease Activity: Results from a Phase 1 Study
Chris Chamberlain¹, Murray Urowitz^2,3, Julie Soranson¹, Mark Watling¹, Peter Colman¹, Olivier Harari¹, Thomas Dorner⁴ and Falk Hiepe⁴, ¹UCB Pharma, Slough, United Kingdom, ²University of Toronto, Toronto, ON, Canada, ³Rheumatology, U of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: CD40 ligand (CD40L) regulates interactions between T cells, B cells, and antigen presenting cells. Considerable evidence suggests CD40L blockade might provide an effective treatment…
Abstract Number: 3223 • 2015 ACR/ARHP Annual Meeting
Anifrolumab, an Anti-Interferon Alpha Receptor Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus (SLE)
Richard Furie¹, JT Merrill², VP Werth^3,4, M Khamashta⁵, K Kalunian⁶, P Brohawn⁷, G Illei⁷, J Drappa⁷, L Wang⁷ and S Yoo⁸, ¹North Shore-LIJ Health System, New York, NY, ²Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Philadelphia V.A. Medical Center, Philidelphia, PA, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Graham Hughes Lupus Research Laboratory, The Rayne Institute, St Thomas' Hospital, London, United Kingdom, ⁶UCSD School of Medicine, La Jolla, CA, ⁷MedImmune, Gaithersburg, MD, ⁸Regenx Bio, Rockville, MD
Background/Purpose: The efficacy and safety of anifrolumab (ANIFR), a type I IFN receptor antagonist, were assessed in a Phase II, randomized, double-blind, placebo-controlled study in…
Abstract Number: 3224 • 2015 ACR/ARHP Annual Meeting
Salivary IL-1 Alpha and IL-1 Beta Levels Are Associated with Oral Mucosal Activity in Behcet’s Disease
Nilufer Alpay Kanitez¹, Bahtiyar Toz¹, Feyza Berktas¹, Sertan Ergun², Meltem Koray², Nuray Gurel Polat³, Burak Erer¹ and Ahmet Gül¹, ¹Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ²Department of Oral Medicine, Istanbul University, Faculty of Dentistry, Istanbul, Turkey, ³Department of Microbiology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey
Background/Purpose: Recurrent oral aphthous ulcers are the common manifestation of the Behçet's disease (BD), and they are indistinguishable from ulcers of recurrent aphthous stomatitis (RAS).…
Abstract Number: 3225 • 2015 ACR/ARHP Annual Meeting
Whole Exome Sequencing Identifies Rare Protein-Coding Variants in Behcet’s Disease
Mikhail Ognenovski¹, Paul Renauer¹, Ina Koetter², Joerg C. Henes³, Bruno Casali⁴, Carlo Salvarani⁵, Haner Direskeneli⁶, Kenneth M. Kaufman⁷ and Amr H. Sawalha¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Internal Medicine IV Rheumatology, Asklepios Klinik Altona, Hamburg, Germany, ³Department of Internal Medicine II, Rheumatology Division, University Hospital Tuebingen, Tuebingen, Germany, ⁴Divisione di Biologia Molecolare, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy, ⁵Rheumatology, Arcispedale S.Maria Nuova, Reggio Emilia, Italy, ⁶Department of Rheumatology, Marmara University Faculty of Medicine, Istanbul, Turkey, ⁷Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Behcet’s disease (BD) is a systemic inflammatory disease characterized by recurrent oral and genital ulcers, skin lesions, uveitis, and other organ complications such as…
Abstract Number: 3226 • 2015 ACR/ARHP Annual Meeting
Increased Serum Levels of IgG Antibodies Against to Alpha-Enolase Are Associated with Severity of Oral Ulcers in Patients with Behcet’s Disease
Shin Eui Kang¹, Sang Jin Lee^2,3, Jin Kyun Park^2,4, Joo Youn Lee², Eun Young Lee³, Eun Bong Lee³ and Yeong Wook Song^3,5, ¹Department of Molecular Medicine and Biopharmaceutical Sciences, BK 21 plus Graduate School of Convergence Science and Technology, and College of Medicine or College of Parmarcy, Seoul National University, Seoul, South Korea, ²Department of Molecular Medicine and Biopharmaceutical Sciences, BK21 plus Graduate School of Convergence Science and Technology, and College of Medicine or College of Pharmacy, Seoul National University, Seoul, South Korea, ³Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, ⁴Department of Molecular Medicine and Biopharmaceutical Sciences Graduate School of Convergence Science and Technology, and College of Medicine or College of Pharmacy Seoul National University, Seoul, South Korea, ⁵Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Medicine Seoul National University, Seoul, South Korea
Background/Purpose: Behcet's Disease (BD) is a chronic inflammatory disease characterized by recurrent oral and genital ulcers, skin lesions, uveitis, and arthritis. Although the etiology of…
Abstract Number: 3227 • 2015 ACR/ARHP Annual Meeting
Identification of Novel Protein-Coding Genetic Variants Associated with Takayasu Arteritis
Paul Renauer¹, Patrick Coit¹, Peter A. Merkel² and Amr H. Sawalha¹, ¹Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²Penn Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Takayasu arteritis is a rare large vessel vasculitis of unclear etiology. Previous studies identified associations between Takayasu arteritis and genetic variants within HLA class…
Abstract Number: 3228 • 2015 ACR/ARHP Annual Meeting
Sofosbuvir Plus Ribavirin for Hepatitis C Virus Associated Cryoglobulinemia Vasculitis: Vascuvaldic Study
David Saadoun¹, V Thibault², L Alric³, C Guillaud⁴, H Izzedine², M Costopoulos², L Musset², H Fontaine⁵, C Hezode⁴, S Pol⁵, T Poynard², P Cacoub² and SN SI Ahmed⁶, ¹Department of Internal Medicine and clinical Immunology. French National Reference Center for Autoimmune Diseases. DHU I2B (Inflammation, Immunotherapy and Biotherapy), UPMC, Paris VI, Hôpital Pitié Salpétrière, AP-HP, UPMC, Univ Paris 06, Paris, France, ²CHU Pitie Salpetriere, Paris, France, ³CHU Toulouse, Toulouse, France, ⁴CHU H Mondor, Creteil, France, ⁵CHU Cochin, Paris, France, ⁶CH Orleans, Orleans, France
Background/Purpose: Hepatitis C virus (HCV) is the etiologic agent for most cases of cryoglobulinemia vasculitis (Cryovas). Interferon–containing regimens are associated with important side effects and…
Abstract Number: 3229 • 2015 ACR/ARHP Annual Meeting
Using Exome Sequencing to Identify Novel Genetic Associations with Granulomatosis with Polyangiitis Susceptibility
Angel C.Y. Mak¹, Paul L.F. Tang², Gang Xie³, Pui-Yan Kwok², Paul A. Monach⁴, Simon Carette³, David Cuthbertson⁵, Gary S. Hoffman⁶, Nader A. Khalidi⁷, Curry L. Koening⁸, Carol A. Langford⁶, Carol A. McAlear⁹, Larry W. Moreland¹⁰, Christian Pagnoux³, Philip Seo¹¹, Ulrich Specks¹², Antoine G. Sreih¹³, Steven R. Ytterberg¹⁴, Peter A. Merkel¹⁵, Katherine A. Siminovitch³, Sharon A. Chung¹⁶ and Vasculitis Clinical Research Consortium, ¹Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA, ²Institute for Human Genetics, University of California, San Francisco, San Francisco, CA, ³Mount Sinai Hospital, Toronto, ON, Canada, ⁴Rheumatology, Boston University School of Medicine, Boston, MA, ⁵Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁶Rheumatology, Cleveland Clinic, Cleveland, OH, ⁷McMaster University, Hamilton, ON, Canada, ⁸Rheumatology, University of Utah, Salt Lake City, UT, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ¹¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹²Division of Pulmonary and Critical Care Medicine, Mayo Clinic College of Medicine, Rochester, MN, ¹³Department of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁴Rheumatology Division, Mayo Clinic, Rochester, MN, ¹⁵Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁶Russell/Englemen Rheumatology Research Center, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, University of California, San Francisco, San Francisco, CA
Background/Purpose: Previous genome-wide association studies of granulomatosis with polyangiitis (Wegener’s, GPA) identified common genetic variants associated with susceptibility to GPA. However, since GPA is a…
Abstract Number: 3230 • 2015 ACR/ARHP Annual Meeting
Perceived Barriers in Care for Arthritis
Elizabeth M. Badley¹, Lynn Moore² and Monique A.M. Gignac³, ¹Toronto Western Research Institute, Toronto, ON, Canada, ²The Arthritis Society, Toronto, ON, Canada, ³Instititue for Work and Health, Toronto, ON, Canada
Background/Purpose: To examine current arthritis treatments, barriers to treatment, and perceptions of health care decision making, especially preferences for patient-physician shared input. Methods: A poll…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].